Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that it has filed all quarterly interim financial reports for fiscal year 2026 to May 31, 2026.

With the recent completion of the August 31, 2025, audit, together with the filings of the Company's outstanding interim financial reports for fiscal year 2026, the Company is positioned to satisfy the regulatory requirements necessary for the British Columbia Securities Commission (the "BCSC") to have the current cease trade order (the "CTO") with respect to the Company revoked.

Concurrently, management shall continue with its previously announced application to list its common shares on the Canadian Securities Exchange (the "CSE"). Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. A listing on the CSE will be contingent on the Company satisfying the CSE's listing requirements and being approved for the listing on that exchange

Q3 Fiscal 2026 Highlights

• Revenue of $4.5 million for the period ending Q3 2026

• Gross profit of $0.9M compared to a gross profit of $0.9 million in Q2 2026

• Gross margin of 54.4% compared to a gross margin of 55.9% during Q2 2026

• Cash position of $0.5 million as of May 31, 2026

• Profit of $0.8 million in the Company's Practitioner Training segment as of Q3 2026

Results from Continuing Operations for Q3 Fiscal 2026

Consolidated revenue was substantially unchanged quarter over quarter, decreasing 0.5% from Q2 2026.

Revenue from Cedar Clinical Research ("CCR") increased 29.0%, from $0.9 million in Q2 2026 to $1.2 million in Q3 2026, reflecting a recovery from seasonal variation in clinical trial patient visits.

Revenue from Practitioner Training decreased from $0.7 million in Q2 2026 to $0.4 million in Q3 2026. The decrease reflects the number of participants trained in the period under existing training contracts rather than a reduction in contracted work.

The Practitioner Training segment recorded segment profit of $0.8 million for the nine months ended May 31, 2026 and has been profitable in each quarter since August 31, 2025.

Balance Sheet and Liquidity

Numinus ended the quarter with cash and cash equivalents of $0.5 million and a working capital deficiency of $3.8 million.

Q3 2026 Performance Metrics

Numinus' consolidated financial statements for the year ended August 31, 2025 and for the interim periods ended November 30, 2026, February 28, 2026 and May 31, 2026, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared in accordance with IFRS.

About Numinus

Numinus Wellness Inc. (OTC Pink: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research and training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

SOURCE Numinus Wellness Inc.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These and other risk factors are outlined in our annual information form dated August 28, 2026, which is available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312283

Source: Numinus Wellness Inc.